[Absolute lymphocyte count as a prognostic factor in children with acute lymphoblastic leukemia]

Area of Science:

• Hematology
• Immunology
• Oncology

Context:

• Recent studies suggest absolute lymphocyte count (ALC) as a prognostic indicator in malignant diseases.
• The immune system's response, involving T cells and natural killer cells, is crucial in cancer patient survival.
• Acute lymphoblastic leukemia (ALL) is a common pediatric cancer requiring effective prognostic tools.

Purpose:

• To prospectively assess the prognostic value of ALC in pediatric patients with ALL.
• To determine if ALC measured at specific time points (day 15 and 28) predicts treatment outcomes.
• To evaluate ALC as a predictor of relapse-free survival (RFS) and overall survival (OS) in ALL.

Summary:

• A study of 105 pediatric ALL patients found that an ALC above 1000 cells/μl at day 15 correlated with significantly higher 5-year RFS (83% vs. 51%).
• Similarly, an ALC above 1000 cells/μl at day 28 was associated with improved 5-year OS (86% vs. 66%).
• Multivariate analysis confirmed ALC as a strong predictor, independent of other known prognostic factors, highlighting its utility in de novo ALL.

Impact:

• Demonstrates that ALC is a simple, statistically powerful, and accessible prognostic marker for pediatric ALL.
• Supports the integration of ALC monitoring into routine clinical practice for ALL management.
• Contributes to a growing body of evidence establishing ALC as a valuable prognostic factor across various malignancies.